The Farmak* Company Group has received its first marketing authorization – permission to sell and use its diagnostic contrast agent for magnetic resonance imaging (MRI) in the People’s Republic of China.
The registration of a medicine manufactured by Farmak in China confirms the high quality of the product and demonstrates the company’s ability to effectively respond to the challenges of a complex regulatory environment. The registration procedure in the People’s Republic of China can take from 2 years.
The Farmak brand is actively expanding its presence in the international market, in accordance with the company’s corporate strategy “Farmak 2.0: from local to global success”. The company exports its own products to more than 60 countries around the world, including 15 EU countries, as well as countries in Central and South America, the Middle East, Asia, Africa and Australia.
*Farmak Company Group is a global pharmaceutical business, including two production facilities in Ukraine, a production facility in Spain, as well as 13 international representative offices and marketing and distribution companies in countries such as Poland, the Czech Republic, Slovakia, Great Britain, the UAE, Vietnam, Switzerland, Kazakhstan, Uzbekistan, Kyrgyzstan, Moldova. The Group’s products are exported to more than 60 countries, including 15 EU countries, and are manufactured in accordance with high European GMP (Good Manufacturing Practice) standards.
